Oral Immunostimulant Market Size

Oral Immunostimulant Market size is poised to reach USD 33.6 Billion by the end of 2036, growing at a CAGR of 7.5% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of the oral immunostimulant was USD 23 Billion, which is attributed to the rising cases of chronic diseases like cancer, and cardiovascular diseases which weaken the immune system.

According to a recent report, there were almost 17.8 million deaths in 2019 due to cardiovascular diseases worldwide. Furthermore, the role of oral immunostimulants is crucial in bolstering the immune system which leads to stimulating the market.

In addition, there is a growing demand for oral immunostimulants globally as patients seek comfortable treatment options over other forms of treatment. Oral Immunostimulant is a convenient option for patients as it can be taken in pill or liquid form. Moreover, oral immunostimulant reduces the possible infections and other complications among patients which further boosts the growth of the market.

Frequently Asked Questions (FAQ)

Increasing awareness of Oral immunostimulants, the emergence of technological advancement, aging population being more susceptible to infections are the major factors driving the growth of the oral immunostimulant market.

The market size of oral immunostimulants is anticipated to attain a CAGR of 7.5% over the forecast period, i.e., 2024-2036.

The major players in the market are Step Pharma, Biogen, Abbott, Amgen, Novartis AG, Merck & Co., and others.

The type segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Oral Immunostimulant Market Size